23andMe Releases New Report Revealing Genetic Likelihood of Experiencing Panic Attacks

23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, today released a new report as part of the 23andMe+ sub...

June 22, 2023 | Thursday | Reports
FDA Pilot Program Aims to Reduce Risks of Cancer Biomarker Tests

U.S. Food and Drug Administration announced a new voluntary pilot program for certain oncology drug products used with certain corresponding in vitro diagn...

June 21, 2023 | Wednesday | News
Deloitte Launches 'Illustrate Change' Medical Illustration Library

Deloitte is proud to announce the launch of "Illustrate Change," a project that seeks to build momentum around representation in medical illustrations and ...

June 21, 2023 | Wednesday | News
FDA Approves New Class of Medicines to Treat Pediatric Type 2 Diabetes

"Compared to adults, children with type 2 diabetes have limited treatment options, even though the disease and symptom onset generally progress more rapidl...

June 21, 2023 | Wednesday | News
Abu Dhabi, M42, AbbVie Partner to Advance Personalized Medicine & Genomics

The MoU was signed by Dr. Asma Al Mannaei, Executive Director of the Research and Innovation Center at the Department of Health – Abu Dhabi(DoH), Fra...

June 20, 2023 | Tuesday | News
First Patient Dosed in Telix's Phase II STARBURST Study Expanding TLX250-CDx Indication in Australia

The STARBURST study (ClinicalTrials.gov Identifier: NCT05563272) is a prospective, open label Phase II "basket" study to investigate CAIX expression in pat...

June 19, 2023 | Monday | News
Emgality Shows Promising Results in Landmark Migraine Prevention Trial, Says Eli Lilly Study

Emgality demonstrated robust efficacy for patients consistent with previous studies, although it did not achieve statistical superiority versus active comp...

June 17, 2023 | Saturday | News
QIAGEN's QuantiFERON-TB Gold Plus Shows Unique Clinical Benefits in Tuberculosis Screenings

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) welcomes the publication of a new systematic evaluation that underlines the unique benefits of the compa...

June 16, 2023 | Friday | News
Lexicon Announces FDA Approval of INPEFA™ (sotagliflozin) for Treatment of Heart Failure

INPEFA reduced the risk of total occurrence of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits by 33% compared to ...

June 16, 2023 | Friday | News
Genomill and iCAN Partner to Enhance Cancer Detection Using Biobank Cohort

Genomill, a pioneering precision diagnostics company, brings its cutting-edge Geno1® platform to the collaboration. Genomill's proprietary and patented...

June 14, 2023 | Wednesday | News
Senju Pharma and Novaliq Sign License Agreement for NOV03 Dry Eye Treatment in Japan

"We are very pleased about the cooperation with Novaliq, a pioneer for groundbreaking non-aqueous eye drop technology. With regard to the unique properties...

June 14, 2023 | Wednesday | News
ACROBiosystems Aneuro Teams Up with Diagnostic Biochips for Neuroscience Drug Discovery

Electrophysiology is a critical part of neuroscience research, especially when attempting to elucidate the neural network. Monitoring the brain's field pot...

June 14, 2023 | Wednesday | News
Study Concludes Self-Sampling Using Colli-Pee® Device for HPV Screening Is Both Cost Effective and Could Improve Patient Access

This study, conducted by experts from Aquarius Population Health Limited in London and the University of Manchester, presents valuable insights into the co...

June 14, 2023 | Wednesday | Analysis
Neuronetics Receives 510(k) Clearance for OCD MT Cap for NeuroStar Advanced Therapy

Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life fo...

June 13, 2023 | Tuesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close